Todd Bazemore - 27 Jun 2022 Form 4 Insider Report for Kala Pharmaceuticals, Inc. (KALA)

Role
President and Chief Operating Officer
Signature
/s/ Mary Reumuth, Attorney-in-Fact
Issuer symbol
KALA
Transactions as of
27 Jun 2022
Net transactions value
-$1,144
Form type
4
Filing time
29 Jun 2022, 20:10:18 UTC
Previous filing
28 Jan 2022
Next filing
28 Oct 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KALA Common Stock Sale $1,144 -3,092 -2.6% $0.3700 115,499 27 Jun 2022 Direct F1, F2
holding KALA Common Stock 42 27 Jun 2022 By son
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the reporting person's restricted stock units granted on June 25, 2020.
F2 Includes 58,834 unvested RSUs.

Remarks:

President and Chief Operating Officer